Cowen and Company’s Amicus Therapeutics FOLD Stock Holding History

Cowen and Company’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,600	Closed	-$12.5K	–	613
2022 Q4	$12.5K	Buy	+7,600	New	+$85.6K	﹤0.01%	385
2021 Q4	–	Sell	-71,600	Closed	-$27K	–	685
2021 Q3	$27K	Sell	71,600 -49,500	-41%	-$506K	﹤0.01%	451
2021 Q2	$48K	Sell	121,100 -39,500	-25%	-$386K	﹤0.01%	408
2021 Q1	$101K	Buy	160,600 +65,000	+68%	+$1.01M	0.01%	322
2020 Q4	$154K	Buy	+95,600	New	+$1.96M	0.01%	193
2020 Q3	–	Sell	-20,000	Closed	-$68K	–	467
2020 Q2	$68K	Buy	+20,000	New	+$244K	0.01%	263
2019 Q4	–	Sell	-32,800	Closed	-$1K	–	511
2019 Q3	$1K	Buy	+32,800	New	+$356K	﹤0.01%	441

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cowen and Company's FOLD Position: Q1 2023 in Review

Cowen and Company sold out of Amicus Therapeutics (FOLD) in Q1 2023, closing a stake of 13,001 shares — an estimated $159K sold.

Cowen and Company first reported a position in FOLD in Q1 2021 and held it in 5 quarters. The position peaked at $645K in Q3 2021. 226 funds tracked by Wall St. Rank hold FOLD as of Q1 2023.

Cowen and Company reported no remaining Amicus Therapeutics position as of Q1 2023 after selling out during the quarter.
Cowen and Company sold 13,001 Amicus Therapeutics shares in Q1 2023, an estimated $159K.
Cowen and Company first reported a position in Amicus Therapeutics in Q1 2021 and held it in 5 quarters.
Cowen and Company's Amicus Therapeutics position peaked at $645K in Q3 2021.
226 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.